Drug Trial Radar · NCT05110261
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Nov 24, 2021
Primary completion
Nov 24, 2025
Study completion Nov 24, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- IQVIA RDS Inc.
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 years, up to 1 year
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
Conditions
- Lower Respiratory Tract Infection
Interventions
NirsevimabDrug
Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
PlaceboDrug
Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of medically attended LRTI due to RT-PCR-confirmed RSVTime frame: Day 1 to Day 151
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Changde, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Jiaxing, China
Research Site
Kunming, China
Research Site
Langfang, China
Research Site
Linfen, China
Research Site
Linfen, China
Research Site
Nanjing, China
Research Site
Ningbo, China
Research Site
Sanmenxia, China
Research Site
Sanya, China
Research Site
Shantou, China
Research Site
Shaoxing, China
Research Site
Shenzhen, China
Research Site
Suzhou, China
Research Site
Tangshan, China
Research Site
Tianjin, China
Research Site
Wenzhou, China
Research Site
Xinxiang, China
Research Site
Zhengzhou, China
Research Site
Zhongshan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.